Company Filing History:
2 out of 26 
2 out of 2 Years Active: 2025
Title: Sujun Deng: Innovator in Therapeutic Antibodies
Introduction
Sujun Deng is a prominent inventor based in Cranbury, NJ (US), known for his significant contributions to the field of therapeutic monoclonal antibodies. With a total of 2 patents, he has made remarkable strides in developing innovative solutions for medical treatments.
Latest Patents
Deng's latest patents include an anti-CLDN18.2 antibody and an anti-FXI/FXIa antibody. The anti-CLDN18.2 antibody is designed to specifically bind to CLDN18.2, effectively mediating the killing of cells that express this protein. This invention also encompasses nucleic acid molecules for encoding the antibody and methods for its preparation. Additionally, it includes a pharmaceutical composition for the prevention and treatment of tumors. The anti-FXI/FXIa antibody, on the other hand, is aimed at inhibiting the activity of FXI/FXIa, providing a potential therapeutic avenue for diseases related to coagulation or thromboembolism.
Career Highlights
Throughout his career, Sujun Deng has worked with notable companies such as Sichuan Kelun Biotech Biopharmaceutical Co., Ltd. and Klus Pharma Inc. His work in these organizations has contributed to the advancement of biopharmaceuticals and therapeutic innovations.
Collaborations
Deng has collaborated with esteemed colleagues, including Haijun Tian and Dengnian Liu, further enhancing the impact of his research and inventions.
Conclusion
Sujun Deng's innovative work in the field of therapeutic antibodies showcases his dedication to advancing medical science. His patents reflect a commitment to developing effective treatments for serious health conditions.